Search Results
| Year | ID | Type | Category | Title | Authors |
|---|
| 2021 | Late-Breaking | Disease-modifying therapy |
Lowered COVID-19 mRNA Vaccine Antibody Response in MS Patients Treated with B -Cell Depleting and S1P-Receptor-Targeting Therapies Compared to Controls: An Interim Analysis |
T. Chitnis, S. Conway, M. Houtchens, B. Glanz, M. Polgar-Turcsanyi, T. J. Saraceno, P. Gaitan-Walsh, E. C. Casady, S. Winston-Khan, T. Feldman, E. Sanon, M. Weiner, R. Bakshi, S. Bhattacharyya, G. Bose, K. Galetta, T. Kaplan, C. A. Severson, T. Singhal, L. Stazzone, J. Zurawski, S. Saxena, A. Loven, F. Yusuf, A. Paul, B. C. Healy, and H. L. Weiner |
| 2021 | Late-Breaking | Case Reports/Case Series |
Brief Telehealth Screening of MS Patients in the Medical Setting |
C. S. Bergmann, D. Jackson, R. Render, M. E. Quig, R. L. Kane, M. A. Adamson, and J. Simsarian |
| 2021 | Late-Breaking | Disease-modifying therapy |
Variables Affecting Disease Modifying Therapy Adherence and Impact of Adherence on Multiple Sclerosis Patients (Egyptian experience) |
A. Abdelsalam, R. Elkabany, I. Alahmar, and M. Sabry |
| 2021 | Late-Breaking | Disease-modifying therapy |
B-Cell Depleters Attenuate the Humoral Response to Sars-Cov-2 Vaccines in Multiple Sclerosis Patients: A Case-Control Study |
W. L. Conte |
| 2021 | Late-Breaking | Disease-modifying therapy |
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment |
J. Foley, G. Defer, L. Zhovtis Ryerson, J. A. Cohen, D. L. Arnold, H. Butzkueven, G. Cutter, G. Giovannoni, J. Killestein, H. Wiendl, K. Smirnakis, S. Xiao, G. Kong, R. Kuhelj, and N. Campbell |
| 2021 | Late-Breaking | Disease-modifying therapy |
COVID-19 Vaccine Antigenicity in the Setting of MS Disease Modifying Treatments |
H. Noh, T. Mortensen, and R. H. Dave |
| 2021 | CAM01 | Poster | Complementary and Alternative Therapies |
Remote Art Therapy Activities Proposal during a COVID-19 Pandemic in Multiple Sclerosis |
| 2021 | CAM02 | Poster | Complementary and Alternative Therapies |
Evaluation of a 6 Week Integrative Medicine Workshop Series on Quality of Life, Self-Efficacy and Wellness in MS |
Megan Weigel, DNP, APRN, MSCN, APHN1,2,3, Linda Connelly, PhD, MSH, ARNP, CNOR1 and Mehgan Fox, BSH2, (1)Brooks College of Health, School of Nursing, University of North Florida, Jacksonville, FL, (2)First Coast Integrative Medicine, Jacksonville, FL, (3)oMS Yoga, Inc., Jacksonville Beach, FL |
| 2021 | CAM03 | Poster | Complementary and Alternative Therapies |
Mindfulness Based Art Therapy to Improve Symptoms Among Adults with Multiple Sclerosis |
Pamela K Newland, PhD, RN, Goldfarb School of Nursing, St Louis, IL, Karlie Lading, BS, RN, nursing, Goldfarb School of Nursing, St Louis, MO and Ling Chen, PhD, Biostatistics, Washington University St Louis, St Louis, MO |
| 2021 | CSR01 | Poster | Case Reports / Case Series |
Delayed Visual Improvement in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis |
Alexandra B Kornbluh, MD1, Grant T Liu, MD2 and Sarah E Hopkins, MD, MSPH1, (1)Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA, (2)Ophthalmology, Children’s Hospital of Philadelphia, Philadelphia, PA |
| 2021 | CSR02 | Poster | Case Reports / Case Series |
Non-Intensive Exercise to Prepare for Intensive, Task-Oriented Rehabilitation in People with Progressive Multiple Sclerosis: A Two-Participant Case Study |
Cameron S Mang, PhD1, Kristen E Plandowski, BSc1, Eduardo A Toledo-Aldana, BSc1 and Sarah J Donkers, PT, PhD2, (1)Kinesiology and Health Studies, University of Regina, Regina, SK, Canada, (2)School of Rehabilitation Science, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada |
| 2021 | CSR03 | Poster | Case Reports / Case Series |
Long Arm Serial Casting Results in Decreased Spasticity and Improved Function for Woman with MS |
Christine Hampton, MOT, OTR/L, Shepherd Center, Atlanta, GA |
| 2021 | CSR04 | Poster | Case Reports / Case Series |
Positive Outcome with Alemtuzumab in Hispanic Puerto Rican Woman with Highly Active Multiple Sclerosis after Various Failed Disease Modifying Therapies |
| 2021 | CSR05 | Poster | Case Reports / Case Series |
Immunotherapy-Responsive Post COVID-19 Central Nervous System Inflammatory Syndrome, a Case Report |
Gina S Perez, MD, Courtney Iser, MD, Sara Habib, MD, Juliane Chainakul, APRN-CNS, Sarah Durica, MD, Danny Samkutty, MD, Evgeny Sidorov, MD, Ahmad Al Awwad, MD, Masoom Desai, MD, Jorge Ortiz, MD, Nidhiben Anadani, MD and David Gordon, MD, Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK |
| 2021 | CSR06 | Poster | Case Reports / Case Series |
Case Report: Lama-2 Related Muscular Dystrophy Mimicking Multiple Sclerosis |
Jacqueline Koshorek, DO and Shiv Saidha, MBBCh, MD, MRCPI, Neurology, Johns Hopkins University, Baltimore, MD |
| 2021 | CSR07 | Poster | Case Reports / Case Series |
Case Report of a Severe Cutaneous Lupus Erythematosus Flare in a Patient Treated with Eculizumab for the Treatment of Neuromyeltis Optica Spectrum Disorder |
Jennifer Chester, FNP-BC, MSCN1, Leah Hurd, RN, BSN2, Tyler Kaplan, MD3,4, Mark Box, MD5 and Jeffrey Kaplan, MD2, (1)Kansas City MS Center at College Park Specialty, Overland Park, KS, (2)Kansas City MS Center, College Park Neurology, Overland Park, KS, (3)Rush University Medical Center, Chicago, United States Minor Outlying Islands, (4)University of Utah, Salt Lake City, UT, (5)Rheumatology, Carondolet, Kansas City, MO |
| 2021 | CSR08 | Poster | Case Reports / Case Series |
Bad Lettuce? Frozen Vegetables? Undercooked Steak? Case Report of Systemic Listeria Monocytogenes Infection in a Patient on Dimethyl Fumarate |
Lisa M. Fox, PA-C MPAS, Neurology/Neuroimmunology, Johns Hopkins Medical Center, Baltimore, MD and Scott D. Newsome, DO, MSCS, FAAN, FANA, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD |
| 2021 | CSR09 | Poster | Case Reports / Case Series |
Treatment Resistant Tinea Corporis in Multiple Sclerosis Patients Treated with Ocrelizumab |
Michelle Maynard, PharmD, BCPS, Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI, Carmen Raschka, RN, Neurosciences, Froedtert Hospital, Milwaukee, WI, Mokshal H Porwal, BSc, Medical College of Wisconsin, Milwaukee, WI and Ahmed Z Obeidat, MD, PhD, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI |
| 2021 | CSR10 | Poster | Case Reports / Case Series |
Identifying and Treating Steroid-Induced Psychosis in MS Patients Using Quetiapine |
Olinka K Hrebicek, MD, Neurology, Island Health MS Clinic, Victoria, BC, Canada and Niall I Murphy, BSc, University of Victoria, Victoria, BC, Canada |
| 2021 | CSR11 | Poster | Case Reports / Case Series |
Multiple Sclerosis-like Features in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Red Flag, Red Herring, or Regular Occurrence? |
Samuel B Marcucci, BS1, Rosemarie Walch, DO1, Ameneh Zare-Shahabadi, MD/MPH2, Lawrence P Goldstick, MD1, Allison Jordan, DO1, Roman Kassa, MD/PhD1, Abdelkader Mahammedi, MD3 and Aram Zabeti, MD1, (1)Waddell Center for Multiple Sclerosis, University of Cincinnati, Cincinnati, OH, (2)Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, (3)Department of Radiology, University of Cincinnati, Cincinnati, OH |
| 2021 | CSR12 | Poster | Case Reports / Case Series |
Multiple Sclerosis in a Patient with Neurofibromatosis Type-1 |
Siddharth Ninan, MBBS1, Gershon Timothy, MD, PhD1, Robert Greenwood, MD1, Clara Zelasky, PA-C1, Stephanie Iyer, PharmD, CPP2 and Irena Dujmovic-Basuroski, MD1, (1)Department of Neurology, UNC Hospitals, Chapel Hill, NC, (2)Department of Pharmacy, UNC Hospitals, Chapel Hill, NC |
| 2021 | DMT08 | Poster | Disease-modifying Therapy |
Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis |
| 2021 | DMT09 | Poster | Disease-modifying Therapy |
Assessment of Composite Disability Accumulation of Ponesimod Relative to Teriflunomide in the Optimum Phase 3 Study |
Alexander J. Keenan, MA, MHP, Ibrahim Turkoz, PhD, Robert Murray, MS and Maria Ait Tihyaty, PhD, Janssen Research & Development, Titusville, NJ |
| 2021 | DMT10 | Poster | Disease-modifying Therapy |
MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity |
Alexander Keenan, MD1, Ibrahim Turkoz, PhD1, Robert Murray, MS2 and Maria Ait Tihyaty, PhD1, (1)Janssen Research & Development, Titusville, NJ, (2)Janssen Research & Development LLC, High Wycombe, NJ, United Kingdom |
| 2021 | DMT11 | Poster | Disease-modifying Therapy |
Generic Perceptions: Measuring Opinions of Patients with MS Toward Generic Disease Modifying Therapies (DMTs) |
Amanda Hickman, PharmD, MPH, MSCS, Central Support Team, Trellis Rx, Atlanta, GA |
| 2021 | DMT12 | Poster | Disease-modifying Therapy |
Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study |
| 2021 | DMT13 | Poster | Disease-modifying Therapy |
Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab |
Anne H. Cross, MD1, Silvia Delgado, MD2, Mario Habek, MD3, Maria Davydovskaya, PhD4, Natalia Totolyan, MD5, Ratnakar Pingili, MBBS6, Linda Mancione, BA6, Roseanne Sullivan, PharmD6, Martin Zalesak, MD, PhD7, Wendy Su, PhD8, Krishnan Ramanathan, PhD7, Xavier Montalban, MD, PhD9 and Kevin Winthrop, MD MPH10, (1)Neurology, Washington University School of Medicine, St Louis, MO, (2)Neurology, University of Miami Miller School of Medicine, Miami, FL, (3)University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia, (4)Pirogov Russian National Research Medical University, Moscow, Russian Federation, (5)National Medical University, St Petersburg, Russian Federation, (6)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (7)Novartis Pharma AG, Basel, Switzerland, (8)Autoimmune, TG Therapeutics, Inc, New York, NY, (9)Vall d’Hebron University Hospital, Barcelona, Spain, (10)School of Public Health at Oregon Health & Science University, Portland, OR |
| 2021 | DMT14 | Poster | Disease-modifying Therapy |
Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder |
Benjamin Greenberg, MD1, Dewei She, Ph.D.2, Eliezer Katz, M.D.2 and Bruce A.C. Cree, MD, PhD, MAS3, (1)Department of Neurology, University of Texas Southwestern, Dallas, TX, (2)Viela Bio, Gaithersburg, MD, (3)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA |
| 2021 | DMT15 | Poster | Disease-modifying Therapy |
Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years |
Bruce A.C. Cree, MD, PhD, MAS1, Gavin Giovannoni, MD, PhD2, Ralf Gold, MD3, Robert J. Fox, MD4, Patrick Vermersch, MD, PhD5, Ralph H.B. Benedict, PhD6, Amit Bar-Or, MD7, Nicolas Rouyrre, MSc8, Daniela Piani-Meier, PhD8, Shannon Ritter, MS9, Ajay Kilaru, MBBS8, Frank Dahlke, MD8, Goeril Karlsson, PhD8 and Ludwig Kappos, MD10, (1)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (2)Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, (3)Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, (4)Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, (5)Univ. Lille, Inserm U1172, CHU Lille, FHU Precise, Lille, France, (6)Jacobs Multiple Sclerosis Center, University at Buffalo, Buffalo, NY, (7)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (8)Novartis Pharma AG, Basel, Switzerland, (9)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (10)Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland |
| 2021 | DMT16 | Poster | Disease-modifying Therapy |
Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders |
Calin Dumitrescu, Medical Student Scholar, Neurology, Medical College of Wisconsin, Milwaukee, WI, Amber Salter, PhD, Biostatistics, Washington University in St. Louis, St. Louis, MO, Michelle Maynard, PharmD, BCPS, Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI and Ahmed Z Obeidat, MD, PhD, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI |
| 2021 | DMT17 | Poster | Disease-modifying Therapy |
Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with Suboptimal Response to Prior Disease-Modifying Therapies: Data from the CASTING Study |
| 2021 | DMT18 | Poster | Disease-modifying Therapy |
Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World |
Chinmay Deshpande, PhD, BPharm1, Mengru Wang, MS2, Roshani Shah, MPH3, Yutong Chang, MS2, Fei Yang, PhD1, Wing Chow, PharmD, MPH1 and Gina M Cox, PhD1, (1)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (2)KMK Consulting, Inc., Morristown, NJ, (3)Previously employed by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, NJ |
| 2021 | DMT19 | Poster | Disease-modifying Therapy |
Daniel Kantor, MD1, Timothy Pham, MS2, Xiu Chen, PhD2, Mayank Mittal, PhD2 and Qian Xia, PhD2, (1)Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, (2)Bristol Myers Squibb, Princeton, NJ |
| 2021 | DMT20 | Poster | Disease-modifying Therapy |
Number-Needed-to-Treat (NNT) to Prevent One Relapse in Recent Teriflunomide-Controlled Clinical Trials in Relapsing MS |
Daniel Kantor, MD, Florida Atlantic University, Boca Raton, FL |
| 2021 | DMT21 | Poster | Disease-modifying Therapy |
Number-Needed-to-Harm (NNH) in Alemtuzumab and Ocrelizumab Pivotal Clinical Trials in Relapsing MS |
Daniel Kantor, MD, Florida Atlantic University, Boca Raton, FL |
| 2021 | DMT22 | Poster | Disease-modifying Therapy |
Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1) |
Augusto A Miravalle, M.D., Advanced Neurology of Colorado, University of Colorado, Fort Collins, CO, Jacob A Sloane, MD PhD, BIDMC Department of Neurology, Harvard Medical School, Boston, MA, Julie Aldridge, MS, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Billerica, MA, Danielle E Harlow, PhD, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Rockland, MA and Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA |
| 2021 | DMT23 | Poster | Disease-modifying Therapy |
Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder |
Dean Wingerchuk, M.D.1, Achim Berthele, MD2, Kazuo Fujihara, MD3,4,5, Celia Oreja-Guevara, MD6, Ho Jin Kim, MD, PhD7, Michael Levy, MD, PhD8,9, Ichiro Nakashima, MD, PhD4,10, Jacqueline Palace, DM11, Shulian Shang, PhD12, Marcus Yountz, MD12, Larisa Miller, PharmD12 and Sean J Pittock, M.D.13, (1)Mayo Clinic, Scottsdale, AZ, (2)Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany, (3)Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, (4)Tohoku University, Sendai, Japan, (5)Fukushima Medical University, Fukushima City, Japan, (6)Hospital Universitario Clinico San Carlos, Madrid, Spain, (7)Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South), (8)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (9)Johns Hopkins University, Baltimore, MD, (10)Tohoku Medical and Pharmaceutical University, Sendai, Japan, (11)John Radcliffe Hospital, Oxford, United Kingdom, (12)Alexion Pharmaceuticals, Boston, MA, (13)Mayo Clinic, Rochester, MN |
| 2021 | DMT24 | Poster | Disease-modifying Therapy |
Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies |
Denise R. Bruen, MSN1, Meghan Garabedian, CRNP, MSN, MSCN2, Cortnee Roman, MSN, FNP-BC3, Nicholas W. Robinson, MA4, Virginia R. Schobel, MSc4, Jason P. Mendoza, PhD5, James B. Lewin, PharmD5, Mary Zhang, PharmD5 and Sai L. Shankar, PhD5, (1)University of Virginia Neuroscience, Charlottesville, VA, (2)Neurology, Penn Neuroscience Center, Perelmen Center for Advanced Medicine, Philadelphia, PA, (3)Rocky Mountain Multiple Sclerosis Clinic and Research Group, Salt Lake City, UT, (4)Spherix Global Insights, Exton, PA, (5)Biogen, Cambridge, MA |
| 2021 | DMT25 | Poster | Disease-modifying Therapy |
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS |
| 2021 | DMT26 | Poster | Disease-modifying Therapy |
Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Four Data |
Elizabeth A Douglas, MPH, Rosie M Jungquist, B.S., Andrew J Bouley, M.D., Ellen S Lathi, M.D. and Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA |